Medical Service, Department of Veterans Affairs, James H. Quillen VA Medical Center, Johnson City, TN 37614, USA.
Vaccine. 2011 Apr 12;29(17):3169-76. doi: 10.1016/j.vaccine.2011.02.052. Epub 2011 Mar 3.
Vaccination for hepatitis B virus (HBV) in the setting of hepatitis C virus (HCV) infection is recommended, but responses to vaccination are blunted when compared to uninfected populations. The mechanism for this failure of immune response in HCV-infected subjects remains unknown but is thought to be a result of lymphocyte dysfunction during chronic viral infection. We have recently demonstrated that PD-1, a novel negative immunomodulator for T cell receptor (TCR) signaling, is involved in T and B lymphocyte dysregulation during chronic HCV infection. In this report, we further investigated the role of the PD-1 pathway in regulation of CD4(+) T cell responses to HBV vaccination in HCV-infected individuals. In a prospective HCV infected cohort, a poor response rate to HBV vaccination as assayed by seroconversion was observed in HCV-infected subjects (53%), while a high response rate was observed in healthy or spontaneously HCV-resolved individuals (94%). CD4(+) T cell responses to ex vivo stimulations of anti-CD3/CD28 antibodies or hepatitis B surface antigen (HBsAg) were found to be lower in HBV vaccine non-responders compared to those responders in HCV-infected individuals who had received a series of HBV immunizations. PD-1 expression on CD4(+) T cells was detected at relatively higher levels in these HBV vaccine non-responders than those who responded, and this was inversely associated with the cell activation status. Importantly, blocking the PD-1 pathway improved T cell activation and proliferation in response to ex vivo HBsAg or anti-CD3/CD28 stimulation in HBV vaccine non-responders. These results suggest that PD-1 signaling may be involved in impairing CD4(+) T cell responses to HBV vaccination in subjects with HCV infection, and raise the possibility that blocking this negative signaling pathway might improve success rates of immunization in the setting of chronic viral infection.
在丙型肝炎病毒(HCV)感染的背景下,推荐接种乙型肝炎病毒(HBV)疫苗,但与未感染者相比,接种疫苗后的反应较为迟钝。HCV 感染患者免疫反应失败的机制尚不清楚,但据认为是慢性病毒感染期间淋巴细胞功能障碍的结果。我们最近证明,PD-1 是一种新型的 T 细胞受体(TCR)信号负调节剂,参与慢性 HCV 感染期间 T 和 B 淋巴细胞的失调。在本报告中,我们进一步研究了 PD-1 通路在调节 HCV 感染个体对 HBV 疫苗接种的 CD4+T 细胞反应中的作用。在一项前瞻性 HCV 感染队列研究中,我们观察到 HCV 感染患者中 HBV 疫苗接种后的血清转化率较差(53%),而健康或自发性 HCV 缓解患者中则观察到较高的反应率(94%)。我们发现,与接受了一系列 HBV 免疫接种的 HCV 感染个体中对 CD4+T 细胞的抗 CD3/CD28 抗体或乙型肝炎表面抗原(HBsAg)的体外刺激反应相比,HBV 疫苗无应答者的 CD4+T 细胞反应较低。在这些 HBV 疫苗无应答者中,CD4+T 细胞上的 PD-1 表达水平相对较高,与那些有反应的人相比,这与细胞激活状态呈负相关。重要的是,阻断 PD-1 通路可改善 HBV 疫苗无应答者对体外 HBsAg 或抗 CD3/CD28 刺激的 T 细胞激活和增殖。这些结果表明,PD-1 信号可能参与削弱 HCV 感染患者对 HBV 疫苗接种的 CD4+T 细胞反应,并提示阻断这种负信号通路可能提高慢性病毒感染患者免疫接种的成功率。